AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
Alnylam Pharmaceuticals Inc.
AstraZeneca shares fall 9% after heart drug trial falls short of target
Actions of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to…
Citi and others are bullish on biotech, medtech and more
2023 was not a good year for the healthcare sector, but some investors expect it to return this year, highlighting…